Keyphrases
Soft Drugs
100%
Sphingosine-1-phosphate Receptor (S1PR)
100%
Ponesimod
56%
Esters
56%
Visceral Leishmaniasis
50%
Mode of Action
50%
Disubstituted piperazines
50%
Naphthyridine
50%
Antileishmanial Activity
50%
In Vivo Activity
50%
S1PR1
50%
Chagas Disease
50%
Bioisosteric Replacement
25%
Pharmacokinetics
25%
Piperazine Ring
25%
Dundee
25%
Neglected Diseases
25%
Sequestration
25%
Glucuronidation
25%
Tolerability
25%
Mouse Model
25%
Parasitic Infection
25%
Divalent Metal Cations
25%
Transient Bradycardia
25%
Paraoxonase 1 (PON1)
25%
Stability in Plasma
25%
GlaxoSmithKline
25%
Metabolic Stability
25%
Current Treatment
25%
Phase II Clinical Trial
25%
Lymphopenia
25%
Butyrylcholinesterase (BChE)
25%
Esterase
25%
Human Plasma
25%
Causative Agents
25%
Systemic Side Effects
25%
Metabolic Instability
25%
Therapeutic Index
25%
Pharmacokinetic Profile
25%
Trypanosoma Cruzi (T. cruzi)
25%
Psoriasis
25%
Plate-like
25%
Specific Substrate
25%
Medical Intervention
25%
Fast Follower
6%
Animal Disease Models
6%
Inflammatory Skin Diseases
6%
Rapid Development
6%
Systemic Medications
6%
Observed Effects
6%
Pharmacology, Toxicology and Pharmaceutical Science
Sphingosine 1 Phosphate Receptor
100%
Ponesimod
100%
Naphthyridine Derivative
50%
Piperazine Derivative
50%
Structure Activity Relationship
50%
Visceral Leishmaniasis
50%
Topical Agent
50%
Chagas Disease
50%
Drug Concentration
50%
Dermatitis
50%
Phenol
50%
Pharmacokinetics
50%
Diseases
50%
Mouse Model
25%
Esterase
25%
Tolerability
25%
Trypanosoma Cruzi
25%
Aryldialkylphosphatase
25%
Piperazine
25%
Neglected Disease
25%
Divalent
25%
Parasitosis
25%
Therapeutic Window
25%
Clinical Trial
25%
Lymphocytopenia
25%
Psoriasis
25%
Side Effect
25%
Metal Ion
25%